Compare FLUX & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLUX | LEXX |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 8.7M |
| IPO Year | 2019 | 2011 |
| Metric | FLUX | LEXX |
|---|---|---|
| Price | $0.63 | $11.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 431.0K | 106.6K |
| Earning Date | 05-07-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,317,000.00 | $705,923.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.01 | $601.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 126.25 | 52.05 |
| 52 Week Low | $0.47 | $0.35 |
| 52 Week High | $7.55 | $12.89 |
| Indicator | FLUX | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 48.25 | 81.22 |
| Support Level | $0.51 | $0.62 |
| Resistance Level | $0.85 | $12.89 |
| Average True Range (ATR) | 0.09 | 1.14 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 33.28 | 85.30 |
Flux Power Holdings Inc. designs, develops, manufactures, and sells a portfolio of lithium-ion energy storage solutions for the electrification of a range of industrial and commercial sectors, which include material handling, airport ground support equipment (GSE), and stationary energy storage. It offers a high-power battery cell management system(BMS). The BMS serves as the brain of the energy storage solution, managing cell balancing, charging, discharging, monitoring, and communication between the pack and the forklift. The company's product portfolio includes Battery Technology and Energy Management solutions.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.